Dulaglutide, an FDA-approved T2DM therapeutics, is a recombinant fusion protein consisting of two identical DPP-4-resistant modified GLP-1 (7–37), separately fused to each arm of modified IgG4 Fc domain via peptide linkers. The gene discussed is GCG; the disease is type 2 diabetes mellitus.